LYON, France , April 10, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced its participation at the European Association of Urology (EAU) 2014 Annual Congress that will be held in Stockholm on April 11-15, 2014 .

Data Describe HIFU as Therapy for Prostate and Liver Cancer

LYON, France, Sep 15, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was highlighted at the 8th Annual International Symposium on Therapeutic

EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences LYON, France, Feb. 15, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Ablatherm ® -HIFU was featured in presentations at three major U.S.

EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused Ultrasound Foundation LYON, France, March 8, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that the prestigious Focused Ultrasound Foundation,

LYON, France , Nov. 23, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes .

PRESS RELEASE Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Rich Cockrell CG CAPITAL 877.889.1972 rich@cg.capital   EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017 Conference Call

LYON, France , Oct. 11, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the results of a multicentric study using Ablatherm Robotic HIFU which demonstrates promising oncologic outcomes with low side effects.

  LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its participation to two major forthcoming international robotics and urology congresses: EAU : European Association of Urology – Amsterdam July 1-4

ENLIGHT Newsletter We are excited that EDAP continues to make substantial progress with our U.S. clinical ENLIGHT trial. In the attached newsletter, please find a message from Cary Robertson, MD, the trial's Primary Investigator and John Rewcastle, PhD, EDAP's Medical Director, outlining the